ArsenalBio lands $70M cash deal with cancer giant Genentech to develop cell therapy

San Francisco-based ArsenalBio’s designer T cells program is attracting the attention of some big players.

After closing a deal and grabbing $70 million in cash from Bristol Myers Squibb last year, the company is back in the news with a brand new deal, this time with Genentech.